Form 8-K Actinium Pharmaceuticals For: Jun 18

Thu, 18 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260618/26667071.html

Form 8-K Actinium Pharmaceuticals For: Jun 18

Thu, 18 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260618/26667071.html

Actinium presents ATNM-400 data at SNMMI showing activity in lung cancer

Wed, 03 Jun 2026 08:02:57 -0400

Actinium Pharmaceuticals Inc. (NYSE American: ATNM) presented preclinical data on ATNM-400 for non-small cell lung cancer at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting on June 2.

The data showed ATNM-400 demonstrated activity in both KRAS and EGFR mutant lung cancer models. In KRAS-mutant studies, ATNM-400 outperformed standard treatments sotorasib and adagrasib when used alone. The standard treatments increased expression of ATNM-400's target by more than 3.5-fold and enhanced effectiveness when combined with ATNM-400.

In EGFR-mutant models, ATNM-400 combined with osimertinib resulted in complete tumor regression in treated animals. ATNM-400 achieved 75% tumor growth inhibition as a single

Actinium presents ATNM-400 data at SNMMI showing activity in lung cancer

Wed, 03 Jun 2026 08:02:57 -0400

In EGFR-mutant models, ATNM-400 combined with osimertinib resulted in complete tumor regression in treated animals. ATNM-400 achieved 75% tumor growth inhibition as a single

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

Wed, 03 Jun 2026 08:00:00 -0400

New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib as a monotherapy. Treatment with these agents increased expression of the ATNM-400 target greater than 3.5x and enhanced their effect in combination
Additional data in the EGFR-mutant setting demonstrated powerful synergy with osimertinib due to enhanced target expression in treated animals resulting in complete tumor regression in the combination arm
The data with EGFR and KRAS mutations which account for approximately 40-50 percent of all NSCLC cases provide compelling evidence of the potential of ATNM-400 as a monotherapy or in combination with inhibitory agents against these mutations
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

Wed, 03 Jun 2026 08:00:00 -0400
- New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib as a monotherapy. Treatment with these agents increased expression of the ATNM-400 target greater than 3.5x and enhanced their effect in combination
- Additional data in the EGFR-mutant setting demonstrated powerful synergy with osimertinib due to enhanced target expression in treated animals resulting in complete tumor regression in the combination arm
- The data with EGFR and KRAS mutations which account for approximately 40-50 percent of all NSCLC cases provide compelling evidence of the potential of ATNM-400 as a monotherapy or in combination with inhibitory agents against these mutations
  Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
  
  Wed, 03 Jun 2026 08:00:00 -0400
  
  New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib as a monotherapy. Treatment with these agents increased expression of the ATNM-400 target greater than 3.5x and enhanced their effect in combination
  
  Additional data in the EGFR-mutant setting demonstrated powerful synergy with osimertinib due to enhanced target expression in treated animals resulting in complete tumor regression in the combination arm
  
  The data with EGFR and KRAS mutations which account for approximately 40-50 percent of all NSCLC cases provide compelling evidence of the potential of ATNM-400 as a monotherapy or in combination with inhibitory agents against these mutations
  
  Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
  
  Wed, 03 Jun 2026 08:00:00 -0400
  
  New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib as a monotherapy. Treatment with these agents increased expression of the ATNM-400 target greater than 3.5x and enhanced their effect in combination
  
  Additional data in the EGFR-mutant setting demonstrated powerful synergy with osimertinib due to enhanced target expression in treated animals resulting in complete tumor regression in the combination arm
  
  The data with EGFR and KRAS mutations which account for approximately 40-50 percent of all NSCLC cases provide compelling evidence of the potential of ATNM-400 as a monotherapy or in combination with inhibitory agents against these mutations
  
  Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
  
  Wed, 03 Jun 2026 08:00:00 -0400
  
  New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib as a monotherapy. Treatment with these agents increased expression of the ATNM-400 target greater than 3.5x and enhanced their effect in combination
  
  Additional data in the EGFR-mutant setting demonstrated powerful synergy with osimertinib due to enhanced target expression in treated animals resulting in complete tumor regression in the combination arm
  
  The data with EGFR and KRAS mutations which account for approximately 40-50 percent of all NSCLC cases provide compelling evidence of the potential of ATNM-400 as a monotherapy or in combination with inhibitory agents against these mutations
  
  Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
  
  Wed, 03 Jun 2026 08:00:00 -0400
  
  New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib as a monotherapy. Treatment with these agents increased expression of the ATNM-400 target greater than 3.5x and enhanced their effect in combination
  
  Additional data in the EGFR-mutant setting demonstrated powerful synergy with osimertinib due to enhanced target expression in treated animals resulting in complete tumor regression in the combination arm
  
  The data with EGFR and KRAS mutations which account for approximately 40-50 percent of all NSCLC cases provide compelling evidence of the potential of ATNM-400 as a monotherapy or in combination with inhibitory agents against these mutations
  
  Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
  
  Wed, 03 Jun 2026 08:00:00 -0400
  
  New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib as a monotherapy. Treatment with these agents increased expression of the ATNM-400 target greater than 3.5x and enhanced their effect in combination
  
  Additional data in the EGFR-mutant setting demonstrated powerful synergy with osimertinib due to enhanced target expression in treated animals resulting in complete tumor regression in the combination arm
  
  The data with EGFR and KRAS mutations which account for approximately 40-50 percent of all NSCLC cases provide compelling evidence of the potential of ATNM-400 as a monotherapy or in combination with inhibitory agents against these mutations
  
  Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
  
  Wed, 03 Jun 2026 08:00:00 -0400
  
  New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib as a monotherapy. Treatment with these agents increased expression of the ATNM-400 target greater than 3.5x and enhanced their effect in combination
  
  Additional data in the EGFR-mutant setting demonstrated powerful synergy with osimertinib due to enhanced target expression in treated animals resulting in complete tumor regression in the combination arm
  
  The data with EGFR and KRAS mutations which account for approximately 40-50 percent of all NSCLC cases provide compelling evidence of the potential of ATNM-400 as a monotherapy or in combination with inhibitory agents against these mutations
  
  Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros
  
  Wed, 03 Jun 2026 07:25:00 -0400
  
  New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant to all three approved androgen receptor inhibitors (ARPIs) -enzalutamide (Xtandi^®), apalutamide (Erleada^®), and darolutamide (Nubeqa^®)- directly targeting the point of failure for a high proportion of mCRPC patients
  
  ATNM-400 substantially outperformed apalutamide and darolutamide in an ARPI-resistant tumor model, and in combination with either ARPI it showed durable complete responses, supporting both monotherapy and combination strategies in refractory disease similar to prior data with enzalutamide
  
  ATNM-400 delivered superior tumor control as a single bolus or repeat dose with a consistent safety profile and
  
  Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros
  
  Wed, 03 Jun 2026 07:25:00 -0400
  
  New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant to all three approved androgen receptor inhibitors (ARPIs) -enzalutamide (Xtandi^®), apalutamide (Erleada^®), and darolutamide (Nubeqa^®)- directly targeting the point of failure for a high proportion of mCRPC patients
  
  ATNM-400 substantially outperformed apalutamide and darolutamide in an ARPI-resistant tumor model, and in combination with either ARPI it showed durable complete responses, supporting both monotherapy and combination strategies in refractory disease similar to prior data with enzalutamide
  
  ATNM-400 delivered superior tumor control as a single bolus or repeat dose with a consistent safety profile and
  
  Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros
  
  Wed, 03 Jun 2026 07:25:00 -0400
  
  New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant to all three approved androgen receptor inhibitors (ARPIs) -enzalutamide (Xtandi^®), apalutamide (Erleada^®), and darolutamide (Nubeqa^®)- directly targeting the point of failure for a high proportion of mCRPC patients
  
  ATNM-400 substantially outperformed apalutamide and darolutamide in an ARPI-resistant tumor model, and in combination with either ARPI it showed durable complete responses, supporting both monotherapy and combination strategies in refractory disease similar to prior data with enzalutamide
  
  ATNM-400 delivered superior tumor control as a single bolus or repeat dose with a consistent safety profile and
  
  Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros
  
  Wed, 03 Jun 2026 07:25:00 -0400
  
  New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant to all three approved androgen receptor inhibitors (ARPIs) -enzalutamide (Xtandi^®), apalutamide (Erleada^®), and darolutamide (Nubeqa^®)- directly targeting the point of failure for a high proportion of mCRPC patients
  
  ATNM-400 substantially outperformed apalutamide and darolutamide in an ARPI-resistant tumor model, and in combination with either ARPI it showed durable complete responses, supporting both monotherapy and combination strategies in refractory disease similar to prior data with enzalutamide
  
  ATNM-400 delivered superior tumor control as a single bolus or repeat dose with a consistent safety profile and
  
  Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros
  
  Wed, 03 Jun 2026 07:25:00 -0400
  
  New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant to all three approved androgen receptor inhibitors (ARPIs) -enzalutamide (Xtandi^®), apalutamide (Erleada^®), and darolutamide (Nubeqa^®)- directly targeting the point of failure for a high proportion of mCRPC patients
  
  ATNM-400 substantially outperformed apalutamide and darolutamide in an ARPI-resistant tumor model, and in combination with either ARPI it showed durable complete responses, supporting both monotherapy and combination strategies in refractory disease similar to prior data with enzalutamide
  
  ATNM-400 delivered superior tumor control as a single bolus or repeat dose with a consistent safety profile and
  
  Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros
  
  Wed, 03 Jun 2026 07:25:00 -0400
  
  New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant to all three approved androgen receptor inhibitors (ARPIs) -enzalutamide (Xtandi^®), apalutamide (Erleada^®), and darolutamide (Nubeqa^®)- directly targeting the point of failure for a high proportion of mCRPC patients
  
  ATNM-400 substantially outperformed apalutamide and darolutamide in an ARPI-resistant tumor model, and in combination with either ARPI it showed durable complete responses, supporting both monotherapy and combination strategies in refractory disease similar to prior data with enzalutamide
  
  ATNM-400 delivered superior tumor control as a single bolus or repeat dose with a consistent safety profile and
  
  Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros
  
  Wed, 03 Jun 2026 07:25:00 -0400
  
  New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant to all three approved androgen receptor inhibitors (ARPIs) -enzalutamide (Xtandi^®), apalutamide (Erleada^®), and darolutamide (Nubeqa^®)- directly targeting the point of failure for a high proportion of mCRPC patients
  
  ATNM-400 substantially outperformed apalutamide and darolutamide in an ARPI-resistant tumor model, and in combination with either ARPI it showed durable complete responses, supporting both monotherapy and combination strategies in refractory disease similar to prior data with enzalutamide
  
  ATNM-400 delivered superior tumor control as a single bolus or repeat dose with a consistent safety profile and
  
  Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros
  
  Wed, 03 Jun 2026 07:25:00 -0400
  
  New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant to all three approved androgen receptor inhibitors (ARPIs) -enzalutamide (Xtandi^®), apalutamide (Erleada^®), and darolutamide (Nubeqa^®)- directly targeting the point of failure for a high proportion of mCRPC patients
  
  ATNM-400 substantially outperformed apalutamide and darolutamide in an ARPI-resistant tumor model, and in combination with either ARPI it showed durable complete responses, supporting both monotherapy and combination strategies in refractory disease similar to prior data with enzalutamide
  
  ATNM-400 delivered superior tumor control as a single bolus or repeat dose with a consistent safety profile and
  
  Actinium Pharmaceuticals names Steffen Heeger as chief medical officer
  
  Mon, 01 Jun 2026 08:01:20 -0400
  
  Actinium Pharmaceuticals Inc. (NYSE American: ATNM) appointed Steffen Heeger, MD, MSc, as chief medical officer, according to a company statement.
  
  Heeger previously served as chief medical officer at Full-Life Technologies, where he led global development of radiotherapy programs. He also held the CMO position at NBE-Therapeutics, which was acquired by Boehringer Ingelberg for $1.4 billion.
  
  Earlier in his career, Heeger worked at Merck KGaA, where he led clinical development for Erbitux (cetuximab) across multiple cancer types including colorectal, head and neck, gastric, and lung cancers in the United States, Europe, Japan, and China.
  
  At MorphoSys AG, he served as vice president and head
  
  Actinium Pharmaceuticals names Steffen Heeger as chief medical officer
  
  Mon, 01 Jun 2026 08:01:20 -0400
  
  Actinium Pharmaceuticals Inc. (NYSE American: ATNM) appointed Steffen Heeger, MD, MSc, as chief medical officer, according to a company statement.
  
  Heeger previously served as chief medical officer at Full-Life Technologies, where he led global development of radiotherapy programs. He also held the CMO position at NBE-Therapeutics, which was acquired by Boehringer Ingelberg for $1.4 billion.
  
  Earlier in his career, Heeger worked at Merck KGaA, where he led clinical development for Erbitux (cetuximab) across multiple cancer types including colorectal, head and neck, gastric, and lung cancers in the United States, Europe, Japan, and China.
  
  At MorphoSys AG, he served as vice president and head
  
  Actinium Pharmaceuticals names Steffen Heeger as chief medical officer
  
  Mon, 01 Jun 2026 08:01:20 -0400
  
  Actinium Pharmaceuticals Inc. (NYSE American: ATNM) appointed Steffen Heeger, MD, MSc, as chief medical officer, according to a company statement.
  
  Heeger previously served as chief medical officer at Full-Life Technologies, where he led global development of radiotherapy programs. He also held the CMO position at NBE-Therapeutics, which was acquired by Boehringer Ingelberg for $1.4 billion.
  
  Earlier in his career, Heeger worked at Merck KGaA, where he led clinical development for Erbitux (cetuximab) across multiple cancer types including colorectal, head and neck, gastric, and lung cancers in the United States, Europe, Japan, and China.
  
  At MorphoSys AG, he served as vice president and head
  
  Actinium Pharmaceuticals names Steffen Heeger as chief medical officer
  
  Mon, 01 Jun 2026 08:01:20 -0400
  
  Actinium Pharmaceuticals Inc. (NYSE American: ATNM) appointed Steffen Heeger, MD, MSc, as chief medical officer, according to a company statement.
  
  Heeger previously served as chief medical officer at Full-Life Technologies, where he led global development of radiotherapy programs. He also held the CMO position at NBE-Therapeutics, which was acquired by Boehringer Ingelberg for $1.4 billion.
  
  Earlier in his career, Heeger worked at Merck KGaA, where he led clinical development for Erbitux (cetuximab) across multiple cancer types including colorectal, head and neck, gastric, and lung cancers in the United States, Europe, Japan, and China.
  
  At MorphoSys AG, he served as vice president and head
  
  Actinium Pharmaceuticals names Steffen Heeger as chief medical officer
  
  Mon, 01 Jun 2026 08:01:20 -0400
  
  Actinium Pharmaceuticals Inc. (NYSE American: ATNM) appointed Steffen Heeger, MD, MSc, as chief medical officer, according to a company statement.
  
  Heeger previously served as chief medical officer at Full-Life Technologies, where he led global development of radiotherapy programs. He also held the CMO position at NBE-Therapeutics, which was acquired by Boehringer Ingelberg for $1.4 billion.
  
  Earlier in his career, Heeger worked at Merck KGaA, where he led clinical development for Erbitux (cetuximab) across multiple cancer types including colorectal, head and neck, gastric, and lung cancers in the United States, Europe, Japan, and China.
  
  At MorphoSys AG, he served as vice president and head

StreetInsider.com News Articles

Form 8-K Actinium Pharmaceuticals For: Jun 18

Form 8-K Actinium Pharmaceuticals For: Jun 18

Actinium presents ATNM-400 data at SNMMI showing activity in lung cancer

Actinium presents ATNM-400 data at SNMMI showing activity in lung cancer

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros

Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros

Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros

Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros

Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros

Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros

Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros

Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros

Actinium Pharmaceuticals names Steffen Heeger as chief medical officer

Actinium Pharmaceuticals names Steffen Heeger as chief medical officer

Actinium Pharmaceuticals names Steffen Heeger as chief medical officer

Actinium Pharmaceuticals names Steffen Heeger as chief medical officer

Actinium Pharmaceuticals names Steffen Heeger as chief medical officer